NeonMind to Commence
Trading on the OTCQB Venture Market
B.C. - May 28, 2021 -- InvestorsHub NewsWire -- NeonMind
Biosciences Inc. (CSE: NEON) (OTCQB:
an integrated drug development and wellness company focused on the
potential therapeutic uses of psilocybin for treating obesity and
weight management conditions, is pleased to announce that its
shares will commence trading on the OTCQB® Venture Market (the
on May 28, 2021, under the symbol "NMDBF".
The OTCQB, operated
by OTC Markets Group Inc., is designed for
and developing U.S.
and international companies. Companies must be current in their
financial reporting and undergo an annual verification and
management certification process, including meeting a minimum bid
price and other financial conditions. With more compliance and
quality standards, the OTCQB provides investors improved visibility
to enhance trading decisions. The OTCQB is recognized by the United
States Securities and Exchange Commission as an established public
market providing public information for analysis and value of
"With this OTCQB
listing, NeonMind has achieved a significant milestone in its
mission to advance its psilocybin drug development programs," said
Robert Tessarolo, President & CEO of NeonMind. "We expect this
listing to increase our financial capabilities and expand our
exposure to the U.S. investment community. This capital markets
support will be extremely valuable as we continue to execute on our
long-term strategy to advance the use of therapeutic psychedelic
compounds for weight management conditions including obesity, which
is a growing global health crisis."
continue to trade on the Canadian Securities Exchange under its
existing symbol "NEON".
About NeonMind Biosciences Inc.
NeonMind is engaged
in preclinical research to develop potential clinical treatments
and wellness products to address obesity and weight management
conditions and to promote health and wellness. The Company operates
three divisions: (i) a pharmaceutical division
engaged in drug development of psychedelic compounds with two lead
psilocybin-based drug candidates targeting obesity; (ii) a medical
services division focused on launching specialty mental health
clinics that integrate psychedelic therapeutics into traditional
psychotherapy settings; and (iii) a consumer products division that
currently sells mushroom-infused products to promote health and
pharmaceutical division, NeonMind has two distinct psilocybin drug
development programs targeting obesity. In its pharmaceutical
division, NeonMind has two distinct psilocybin drug development
programs targeting obesity. NeonMind's first drug candidate employs
psilocybin as an agonist to the serotonin receptor 5- HT2A, which
is involved in the hallucinogenic effect of psychedelics. The
Company's second drug candidate employs low-dose psilocybin as an
agonist to the 5-HT2C receptor, which controls appetite.
established a medical services division with the goal of launching
NeonMind-branded specialty mental health clinics in Canada that
incorporate evidence-backed innovative treatments to address a
variety of mental health needs.
division currently sells NeonMind branded coffee products in Canada
through NeonMind's direct to consumer e-commerce platform, and it
has plans to launch dietary supplements in the United States
in the near
information on NeonMind, go to www.NeonMindBiosciences.com.
Tessarolo, President & Chief Executive Officer, NeonMind
KCSA Strategic Communications
Securities Exchange has not reviewed, approved nor disapproved the
contents of this news release.
Cautionary Statement Regarding Forward-Looking
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or NeonMind's future performance. The use of any of the
words ``could", "expect", "believe", "will", "projected",
"estimated" and similar expressions and statements relating to
matters that are not historical facts are intended to identify
forward-looking information and are based on NeonMind's current
belief or assumptions as to the outcome and timing of such future
events. Actual future results may differ materially.
In particular, NeonMind's
drug development plans, its ability to retain key personnel, and
its expectation as to the development of its intellectual property
and other steps in its preclinical and clinical drug development
constitute forward-looking information. Actual results and
developments may differ materially from those contemplated by
forward-looking information. Readers are cautioned not to place
undue reliance on forward-looking information. The statements made
in this press release are made as of the date hereof.
disclaims any intention or obligation to publicly update or revise
any forward-looking information, whether
as a result of
new information, future events or otherwise, except as may be
expressly required by applicable securities laws.